Effect of vitamin D3 supplementation on cardiometabolic disease risk among overweight/obese adult males in United Kingdom- A pilot randomised controlled trial
AffiliationUniversity of Chester; Baze University
MetadataShow full item record
AbstractBackground Observational studies suggest links between reduced serum 25(OH)D concentration and increased cardiometabolic disease risk. However, these studies provide limited evidence of causation, with few conclusive randomised controlled trials (RCT) having been carried out to date. This RCT investigated the effect of vitamin D3 supplementation on vascular function and cardiometabolic disease risk markers, in fifty-five healthy males aged 18-65 years with plasma 25(OH)D concentration <75nmol/L and BMI ≥24.9kg/m2. Method Participants were assigned to consume 125µg/day (5,000 IU/day) vitamin D3 or placebo for 8-weeks. Blood samples and vascular function measures were obtained at baseline, week 4 and week 8. The primary outcome was arterial stiffness, an indicator of cardiovascular diseases risk (CVD), assessed by pulse wave velocity. Biomarkers of CVD risk, insulin resistance and endothelial function were measured using enzyme linked immunosorbent assay. Results Daily oral intake of 125µg supplemental vitamin D3 led to a significant improvement in plasma 25(OH)D concentrations over the 8-week intervention in the vitamin D group compared to the change in the placebo group (P ˂ 0.001). In the vitamin D group the baseline mean (±SD) 25(OH)D concentration was 38.4 ± 15.9 and this increased to 72.8 ± 16.1 nmol/L after 8 weeks of supplementation. The intervention had no effect on arterial stiffness, as measured by pulse wave velocity (PWV) but vitamin D3 supplementation did lead to a decrease in mean (±SD) brachial pulse pressure from baseline to 8 weeks, by − 2.9 ± 3.4 mmHg, (P = 0.027) in the vitamin D group compared to the same period in the placebo group. The intervention had no effect on the remaining cardiometabolic parameters. Conclusion Overall, treatment significantly improved brachial pulse pressure but no other cardiometabolic disease risk markers. To follow on from this pilot RCT, future large-scale clinical trials over longer durations may offer further insights. Clinical trial registration http://www.clinicaltrials.gov NCT02359214.
CitationAgbalalah, T., & Mushtaq, S. (2022). Effect of vitamin D3 supplementation on cardiometabolic disease risk among overweight/obese adult males in United Kingdom - A pilot randomised controlled trial. Journal of Human Nutrition and Dietetics, vol(issue), pp. https://doi.org/10.1111/jhn.13021
DescriptionThis is the peer reviewed version of the following article: [Agbalalah, T., & Mushtaq, S. (2022). Effect of vitamin D3 supplementation on cardiometabolic disease risk among overweight/obese adult males in United Kingdom - A pilot randomised controlled trial. Journal of Human Nutrition and Dietetics, vol(issue), pp. https://doi.org/10.1111/jhn.13021], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International